Filtered By:
Condition: Atrial Fibrillation
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 1538 results found since Jan 2013.

Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
The safety of intravenous thrombolysis in patients taking rivaroxaban has not been well established. We retrospectively analyzed the outcomes of all patients who received thrombolytic therapy in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). A review of medical and adverse event records for patients receiving thrombolytic therapy while enrolled in ROCKET AF was performed to determine their baseline characteristics, indications for thrombolysis, and type of agent used.
Source: The American Journal of Cardiology - August 7, 2017 Category: Cardiology Authors: Sean T. Chen, Anne S. Hellkamp, Richard C. Becker, Scott D. Berkowitz, G ünter Breithardt, Keith A.A. Fox, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Daniel E. Singer, Manesh R. Source Type: research

Antithrombotic Treatments in Patients with Acute Ischemic Stroke and Non-Valvular Atrial Fibrillation Before Introduction of Non-Vitamin K Antagonist Oral Anticoagulants Into Practice in Korea
This multicenter observational study aimed to describe patterns of long-term antithrombotic use in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF) in Korea and their impacts on clinical events before introduction of non-vitamin K antagonist oral anticoagulants (NOAC) into practice in 2015.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: H Bae, J Heo, K Jung, Y Lee, K Hong, W Seo, J Koo, J Cha, MJ Lee, B Seo, Y Kim, S Kang, J Seok, J Lee, C Chung Source Type: research

Cost-Effectiveness of Apixaban In Prevention of Stroke And Systemic Embolism In The Czech Republic
Apixaban is an oral anticoagulant, direct factor Xa inhibitor. The aim of the analysis was to compare costs and effectiveness of apixaban in the first line prevention of stroke and systemic embolism in vitamin K antagonist (VKA) suitable patients with atrial fibrillation. The analysis was conducted from the perspective of the public healthcare payer in the Czech Republic.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Kolek, T Spousta, M Karbusicka, P Vothova, P Mazan, J Duba Source Type: research

Portuguese Observational Study of Ischaemic Stroke in Patients Medicated with Non-Vitamin K Antagonist Oral Anticoagulants
Conclusion: Preadmission anticoagulation with NOACs in AIS has a functional impact similar to that of VKAs.Eur Neurol 2018;79:108 –112
Source: European Neurology - February 8, 2018 Category: Neurology Source Type: research

Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment
Whether carotid atherosclerosis is associated with an increased risk for ischemic stroke in patients with atrial fibrillation (AF) on anticoagulant treatment is undefined. To explore this association, patients with AF on treatment with vitamin K antagonists were included in a multicenter, prospective study.
Source: Atherosclerosis - February 22, 2018 Category: Cardiology Authors: Cecilia Becattini, Francesco Dentali, Giuseppe Camporese, Agnese Sembolini, Elena Rancan, Chiara Tonello, Giorgia Manina, Seena Padayattil, Giancarlo Agnelli Source Type: research

Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding
ConclusionsThe comparative cost effectiveness of edoxaban and warfarin is highly sensitive to TTR. At the $US100,000/QALY willingness-to-pay threshold, our results suggest that warfarin is the most cost-effective treatment for patients who can achieve a TTR of 70%.
Source: American Journal of Cardiovascular Drugs - May 9, 2018 Category: Cardiology Source Type: research

Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke, and venous and arterial thromboembolism.
Authors: Seoane L, Cortés M, Aris Cancela ME, Furmento J, Baranchuk A, Conde D Abstract INTRODUCTION: Until recently, vitamin K antagonists were the only drugs available for long-term anticoagulation. The use of these drugs is laborious due to their variable pharmacokinetics and pharmacodynamics. The advent of direct oral anticoagulants has produced a paradigm shift due to their low incidence of drug interactions, their stable plasma levels and their lack of monitoring. Rivaroxaban, a factor Xa inhibitor, has been tested in different clinical scenarios and has proved to be effective and safe, even increasing the s...
Source: Expert Review of Cardiovascular Therapy - June 6, 2018 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients With Atrial Fibrillation Cochrane Corner
Source: Stroke - June 25, 2018 Category: Neurology Authors: Karsten M.H. Bruins Slot, Eivind Berge Tags: Atrial Fibrillation, Anticoagulants, Cerebrovascular Disease/Stroke Cochrane Corner Source Type: research

Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Authors: PMID: 30566008 [PubMed - in process]
Source: Circulation - December 18, 2018 Category: Cardiology Tags: Circulation Source Type: research

Stroke risk assessment in atrial fibrillation: Beyond atrial rhythm
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is responsible for at least 20% of all strokes. Moreover, strokes associated to AF are largely avoidable, as the use of anti-vitamin K drugs can prevent>65% of all strokes, and direct oral anticoagulants con reduce the rate of stroke by a further 19% [1].
Source: International Journal of Cardiology - May 22, 2019 Category: Cardiology Authors: Giovanni Luca Botto, Francesco Maria Brasca Tags: Editorial Source Type: research

Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke
- The CATALYST trial will examine Abbott's Amplatzer ™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation
Source: Abbott.com - February 3, 2020 Category: Pharmaceuticals Source Type: news

Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study
Direct oral anticoagulants (DOACs) are not only increasingly being used for the initial stroke prevention therapy but progressively also substitute vitamin K antagonist (VKA) treatment in patients with non-val...
Source: BMC Medicine - August 27, 2020 Category: Internal Medicine Authors: Lena M. Paschke, Kerstin Klimke, Attila Altiner, Dominik von Stillfried and Maike Schulz Tags: Research article Source Type: research

Malignant Left Atrial Appendage Morphology: Current Classification vs H-L System
In non-valvular atrial fibrillation (AF), more than 90% of thrombus formation occurs in the left atrial appendage (LAA).1-3 Current guidelines have established direct oral anticoagulants (DOACs) as the treatment of choice in patients with AF and high risk of stroke or transient ischemic attack (TIA), while vitamin K antagonists (VKA) can be considered in patients not suitable for DOACs.4,5 This strategy significantly reduces the risk of thromboembolism; however, there is a subset of patients that suffer recurrent embolic strokes despite appropriate anticoagulant therapy, known as malignant LAA.
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2020 Category: Neurology Authors: Paloma Parra-D íaz, Luisa Salido-Tahoces, Ana Pardo-Sanz, Álvaro Beltrán-Corbellini, Fernando Rodríguez-Jorge, Juan Luis Chico-García, Sebastián García-Madrona, Consuelo Matute-Lozano, Rocío Vera-Lechuga, Antonio Cruz-Culebras, Jaime Masjuan, Alic Source Type: research

Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation
Expert Opin Investig Drugs. 2021 Mar 8. doi: 10.1080/13543784.2021.1897786. Online ahead of print.ABSTRACTINTRODUCTION: Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia globally and is associated with ischemic stroke and heart failure. Patients with atrial fibrillation are typically prescribed long term anticoagulants in the form of either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants; however, both carry a potential risk of adverse bleeding.AREAS COVERED: This paper sheds light on emerging anticoagulant agents which target clotting factors XI and XII, or their activated forms...
Source: Expert Opinion on Investigational Drugs - March 8, 2021 Category: Drugs & Pharmacology Authors: Robert Bentley Lewis J Hardy Laura J Scott Parveen Sharma Helen Philippou Gregory Y H Lip Source Type: research